Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

NCT01239758 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated based on preliminary safety data.

Conditions

Duchenne Muscular Dystrophy

Interventions

BIOLOGICAL: ACE-031 (Extension of cohort 1 from core study, A031-03)
BIOLOGICAL: ACE-031 (Extension of cohort 2 from core study, A031-03)
BIOLOGICAL: ACE-031 (Extension of cohort 3 from core study, A031-03)

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA